<DOC>
	<DOCNO>NCT01696071</DOCNO>
	<brief_summary>Determine 24-hour FEV1-profile tiotropium solution inhalation 4 week treatment period 5 mcg tiotropium administer daily even 2.5 mcg tiotropium administer twice daily ( morning evening ) . In addition compare 24 hour pharmacokinetic profile 5 mcg tiotropium administer daily 2.5mcg tiotropium administer twice daily pharmacokinetic sub-investigation .</brief_summary>
	<brief_title>Comparison Two Daily Dose Regimens Tiotropium 5 µg Once Daily Tiotropium 2.5 µg Twice Daily 4 Weeks Top Maintenance Therapy With Inhaled Corticosteroid Controller Medication</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criterion : 1 . All patient must sign date Informed Consent Form consistent ICHGCP guideline local legislation prior participation trial . 2 . Male female patient age least 18 year Visit 0 75 year Visit 0 . 3 . All patient must least 3 month history asthma time enrolment ( sign ICF ) trial . The initial diagnosis asthma must make patient 's age 40 . 4 . All patient must prebronchodilator FEV1 = 60 % predict = 90 % predict normal Visit 1.Variation absolute prebronchodilator FEV1 value Visit 1 Visit 2 must within ± 30 % . 5 . Patient 's diagnosis asthma confirm Visit 1 bronchodilator reversibility ( ie 10 minute prior 1530 minute inhalation 400 µg salbutamol ) define FEV1 increase = 12 % = 200 mL . 6 . All patient must diagnosis moderate persistent asthma must symptomatic despite current maintenance treatment medium dose ICS . 7 . All patient must symptomatic Visit 1and Visit 2 define ACQ mean score = 1.5 . 8 . All patient must maintenance treatment stable medium daily dose ICS least 4 week prior Visit 1 . 9 . Patients must neversmokers exsmokers stop smoke least one year prior enrolment ( Visit 0 ) smoke history le 10 packyears Visit 0 . 10 . Patients must able use Respimat inhaler correctly . 11 . Patients must able perform trial related procedure include technically acceptable pulmonary function test use AM3 ( ediary ) compliance least 80 % require . 12 . Patients take chronic pulmonary medication allow study protocol must willing continue therapy entire duration study ( exception : time acute disease deterioration ) . Exclusion criterion : 1 . Patients significant disease asthma . A significant disease define disease , opinion investigator , may ( ) put patient risk participation trial , ( ii ) influence result trial , ( iii ) cause concern regard patient 's ability participate trial . 2 . Patients clinically relevant abnormal screen hematology blood chemistry Visit 1 abnormality defines significant disease define exclusion criterion . 1 . 3 . Patients require 12 puff rescue medication ( salbutamol MDI ) per 24 hour 2 consecutive day Visit 1 Visit 2 ( screen period ) . 4 . Patients recent history ( ie six month less ) Acute Coronary Syndrome ( STEMI , nonSTEMI , Unstable Angina Pectoris ) prior Visit 1 ( screen ) . 5 . Patients hospitalise cardiac failure past year prior Visit 1 ( screen ) . 6 . Patients unstable lifethreatening cardiac arrhythmia cardiac arrhythmia require intervention change drug therapy within past year prior Visit 1 ( screen ) . 7 . Patients lung disease asthma ( eg COPD ) . 8 . Patients know active tuberculosis . 9 . Patients malignancy patient undergone resection , radiation therapy chemotherapy within last five year prior Visit 1 ( screen ) . Patients treat basal cell carcinoma allow . 10 . Patients undergone thoracotomy pulmonary resection . Patients history thoracotomy reason evaluate per exclusion criterion . 1 . 11 . Patients significant alcohol drug abuse Investigator 's assessment within past two year prior Visit 1 ( screen ) . 12 . Patients currently pulmonary rehabilitation program complete pulmonary rehabilitation program 6 week prior Visit 1 ( screen ) . 13 . Patients know hypersensitivity anticholinergic drug , BAC , EDTA component study medication delivery system . 14 . Pregnant nursing woman , include female patient positive ßHCG test Visit 1 . 15 . Female patient childbearing potential use highly effective method birth control . As defined ICH ( M3 ) [ R091400 ] , note 3 , highly effective method birth control define , alone combination , result low failure rate ( ie le 1 % per year ) use consistently correctly , implant , injectables , combine oral contraceptive , intrauterine device ( IUDs ) , sexual abstinence vasectomise partner . Barrier contraceptive ( eg male condom diaphragm ) acceptable use combination spermicide ( eg foam , gel ) . Female patient consider childbearing potential unless surgically sterilise hysterectomy bilateral tubal ligation/salpingectomy , postmenopausal least two year . 16 . Patients treat restricted medication prior Visit 1 and/or screen period . 17 . Patients asthma exacerbation respiratory tract infection four week prior Visit 1 screen period . Visit 1 and/or Visit 2 postpone case asthma exacerbation respiratory tract infection . Refer Section 6.1 information reschedule visit . 18 . Patients currently participate another trial participate another trial within one month prior Visit 0 , patient previously randomise trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>